William Patrick Slattery, President and CEO, brings over 35 plus years of senior executive experience to Nieuw Amsterdam Advisors. He is regarded as one of the top marketing experts in the industry noted for combining a calm demeanor with a shrewd negotiation ability to navigate the most challenging business transactions on behalf of our clients. He is a graduate of the University of Notre Dame’s Mendoza College of Business Administration. William Patrick Slattery found early success as a Vice President at RCA Global before being offered an opportunity to live and work in London for two British financial research firms, Extel and IFR as a Senior Managing Partner. After several years of multi-million dollar sales generation, Mr Slattery returned to New York after assisting in the very successful sale of IFR to a Canadian concern. Back in New York, William Patrick Slattery was approached by two large family offices to assist them in finding potential business opportunities. Those families have since grown into a substantial network of family offices that Mr. Slattery maintains close relations to this day. Through a series of business connections, William Slattery was asked to help create Nieuw Amsterdam Advisors to fill the great need of finding and assisting emerging groundbreaking life sciences companies find the support traction needed to bring their technologies to the world.
Twenty-five years in management consulting, finance, investment and product management with cross industry experience in med tech, biotech, consumer products and financial services. Former key roles in Fortune 500 companies including, Citibank, JP Morgan Chase, Dentsply International, and Colgate-Palmolive.
MS in Marketing from University of Illinois, BS in Economics from University of International Business and Economics, China. Advanced courses in investment finance from Columbia University and accounting from Stern Business School of New York University. Lora Feng joined William Patrick Slattery to take Nieuw Amsterdam Advisors to new heights.
A CPA and MBA, Mr. Piccolo began his career in 1977 at KPMG serving as an original member of The Private Business Advisory Services Group. After KPMG, Mr. Piccolo assumed the role of CFO & EVP for I. Miller Shoes and was awarded a board seat after a series of innovative financial implementations. Mr. Piccolo was eventually recruited by Alfred Dunhill of London, Inc to serve as it’s CFO and EVP. Mr. Piccolo was widely credited for being instrumental in converting the British luxury retailer and smoker’s products into a purveyor of high end men’s fashions. He also expanded Dunhill’s American presence from 8 stores to over 14 with a marked increase in profitability.
In 1988, Mr. Piccolo became a founder and president of Piccolo Business Advisory (www.piccolobusinessadvisory.com) a management consulting firm that has a specialty in turn around management situations. Mr. Piccolo provides financial operation and systems expertise especially in life sciences companies in the US and international.
Having qualified as a chartered accountant at Arthur Anderson, Martin became the founder and global manager of the corporate finance firm.
With more than 1,000 professionals in 35 countries and over $1 billion in annual revenues the firm covered transaction advisory and lead execution services from M&A to IP0’s and corporate restructurings.
Among Martin’s notable clients were two start ups to FTSE 100 listed companies. Martin has been involved in several leading edge private and public technology as a director, adviser and/or investor. Martin is also founding director (non-executive) of a life sciences investment firm NCL Technology Ventures.
Robert began his career at Barclays, PLC moving into the investment banking arm BZW to focus on M&A advisory and capital markets. In 1998, he joined Martin at Arthur Anderson and led efforts to consolidate the corporate finance business from New York and London.
A generalist, Robert has been advising U.K. companies for the last 15 years with a focus on energy, healthcare and tech space.
Recent transactions include significant equity placement into leading U.K. biotech, advising a Russell Group University on a tech spin-out, preparation of a waste to energy technology for Series A, advising an innovative med tech company on capital structure and introduction into US capital market.